Artículos seleccionados

El experto opina

Artículos seleccionados

Sustainable public health systems for rare diseases

Ferrelli RM, Egle Gentile A, De Santis M, Taruscio D. Sustainable public health systems for rare diseases. Ann Ist Super Sanita. 2017; 53(2): 170-175.

Comentado por:

Marta Trapero-Bertran
Profesora titular e investigadora de la Universitat Internacional de Catalunya (UIC)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen

Giannuzzi V, Conte R, Landi A, Ottomano SA, Bonifazi D, Baiardi P, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017; 12: 64

Comentado por:

Jaime Espín
Profesor de la Escuela Andaluza de Salud Pública

Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research

Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research.©World Health Organization 2015. Regional Office for Europe

Comentado por:

Albert Figueras
Profesor del Departamento de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

Gammie T, Lu CY, Babar ZU-D. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS ONE. 2015; 10(10): e0140002.

Comentado por:

Jorge Mestre-Ferrandiz
Director de Consultoría. Office of Health Economics. Londres.

Mejoras de la regulación de los medicamentos huérfanos y predicciones de su impacto presupuestario en Europa

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe

Estimating the budget impact of orphan medicines in Europe: 2010 – 2020

Gutierrez L, Patris J, Hutchings A, Cowell W. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis 2015, 10:53. doi10.1186/s13023-015-0269-y. 

Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 – 2020. Orphanet J Rare Dis 2011, 6:62. 

Comentados por:

Carlos Campillo-Artero
Servicio de Salud de les Illes Balears, Centre de Recerca en Economía i Salut, Universitat Pompeu Fabra

Dr. Julio Martínez
Coordinador Clínico. Jefe del Servicio de Farmacia. Hospital Universitario Vall d'Hebron. Barcelona

Página 3 de 3